Posted by Clinical Lab Products | Jun 12, 2008 | Cancer, Miscellaneous |
Rosetta Genomics Ltd, Israel, which develops microRNA-based diagnostics and therapeutics, has signed a binding term sheet for $2.9 million to purchase Parkway Clinical Laboratories Inc, Bensalem, Pa, a privately owned CLIA-certified lab.
Read MorePosted by Clinical Lab Products | Apr 17, 2008 | Cancer, Miscellaneous |
Irregular molecules in the lining of the mouth, the saliva, the fallopian tube, or the bladder can identify early stage cancer, according to research presented this week at the annual meeting of the American Association for Cancer Research.
Read MorePosted by Clinical Lab Products | Apr 14, 2008 | Cancer, Miscellaneous |
Genetic variations ensure no two people or their cancers are identical, and researchers may provide more precise and effective treatment wielding tools and knowledge that predict how individuals will respond to cancer therapy.
Read MorePosted by Clinical Lab Products | Mar 7, 2008 | Cancer, Lung Cancer, Molecular Diagnostics |
Abbott, Abbott Park, Ill, has inked an agreement with Genentech Inc, F Hoffmann-La Roche Ltd, and OSI Pharmaceuticals Inc to develop a gene test to potentially assess clinical benefits of an oral tablet for treating patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
Read MorePosted by Clinical Lab Products | Feb 21, 2008 | Cancer, Miscellaneous |
Genzyme Genetics, Cambridge, Mass, has signed a sublicense agreement with DxS Ltd, Manchester, UK in which it will grant DxS worldwide rights with the exception of North America and Hong Kong for diagnostic testing of epidermal growth factor receptor mutations in non-small cell lung cancer.
Read More